RxDoctor Payments Data

Muhammad Khakwani, MD

Interventional Cardiology · Avondale, AZNPI 1710353123

Payments from drug & device makers

$26,535in general payments, 2019–2025

Across 186 payments — averaging $142.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Angiodynamics, Inc.$7K
  • Abbott$4K
  • Terumo Medical Corporation$2K
  • Edwards Lifesciences$2K
  • Shockwave Medical, Inc$800
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$2,1008%
  • Grants$7,60229%
  • Travel & lodging$3,38013%
  • Food & beverage$6,21023%
  • Education$6753%
  • Other$6,56725%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,535 in reported general payments places this provider in the 65th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$374,692
Medicare patients
1,024
Services billed
2,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$107,790
XareltoRivaroxaban41$67,860
EntrestoSacubitril/Valsartan34$56,024
FarxigaDapagliflozin Propanediol40$40,357
JardianceEmpagliflozin11$15,229
Metoprolol Succinate398$3,623
ClopidogrelClopidogrel Bisulfate206$2,364
Atorvastatin Calcium229$2,085
Rosuvastatin Calcium115$1,931
Amlodipine Besylate254$1,465
Chlorthalidone56$1,253
Carvedilol113$1,112
Losartan Potassium126$1,022
Diltiazem 24hr Er (Cd)Diltiazem Hcl25$907
Nifedipine ErNifedipine34$849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$107,79079 claims
Johnson & JohnsonXarelto$126$67,86041 claims
NovartisEntresto$126$56,02434 claims
AstraZenecaFarxiga$181$40,35740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Avondale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →